[en] BM-531 (N-tert-butyl-N'-[(2-cyclohexylamino-5-nitrobenzene)sulfonyl]urea), a torasemide derivative, is a novel noncarboxylic thromboxane receptor antagonist and thromboxane synthase inhibitor. Indeed, its affinity for human washed platelet TXA2 receptors labeled with [3H]SQ-29548 (IC50 = 0.0078 microM) is higher than sulotroban (IC50 = 0.93 microM) and SQ-29548 (IC50 = 0.021 microM). Moreover, BM-531 is characterized by a potent antiaggregatory property. Indeed, on one hand, in human citrated platelet-rich plasma BM-531 prevents platelet aggregation induced by arachidonic acid (600 microM) (ED100 = 0.125 microM), U-46619, a stable TXA2 agonist (1 microM) (ED50 = 0.482 microM) or collagen (1 microgram/mL) (percentage of inhibition: 42.9% at 10 microM) and inhibits the second wave of ADP (2 microM)-induced aggregation. On the other hand, when BM-531 is incubated in whole blood from healthy donors, the closure time measured by the recently developed platelet function analyser (PFA-100) is significantly prolonged. In addition, at the concentrations of 10 and 1 microM, BM-531 totally prevents the production of TXB2 by human platelets activated by arachidonic acid. Finally, at 10 microM, BM-531 significantly prevents rat fundus contractions induced by U-46619 but not by prostacyclin. These results suggest that BM-531, which is devoid of the diuretic property of torasemide, can be regarded as a promising antiplatelet agent.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Dogné, J. M.
Rolin, S.
de Leval, X.
Benoit, P.
Neven, P.
Delarge, J.
Kolh, Philippe ; Université de Liège - ULiège > Département des Sciences biomédicales et précliniques > Service de Biochimie et de Physiologie générales, humaines, normales et pathologiques
Damas, Jacques ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
David, Jean-Louis ; Université de Liège - ULiège > Services généraux (Faculté de médecine) > Relations académiques et scientifiques (Médecine)
Masereel, B.
Language :
English
Title :
Pharmacology of the Thromboxane Receptor Antagonist and Thromboxane Synthase Inhibitor Bm-531
(1994) Collaborative overview of randomised trials of antiplatelet therapy: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308:81-106.
Buchanan M.R., Brister S.J. (1995) Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically. Can J Cardiol 11:221-227.
Cleland J.G., Bulpitt C.J., Falk R.H. (1995) Is aspirin safe for patients with heart failure?. Br Heart J 74:215-219.
Coleman R., Humphrey P., Kennedy I., Levy G., Lumley P. (1981) Comparison of the actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations. Br J Pharmacol 73:773-778.
Cozzi P., Salvati P. (1991) Thromboxane synthase inhibitors and TXA2 antagonists. Curr Opin Ther 1343-1373.
De Clerck F., Beetens J., Van de Water A., Vercammen E., Janssen P.A. (1989) R 68 070: Thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule. II. Pharmacological effects in vivo and ex vivo. Thromb Haemost 61:43-49.
Dognet J.M., De Leval X., Neven P. (2000) Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function. Prostaglandins Leukot Essent Fatty Acids 62:311-317.
Ellis E., Oelz O., Roberts L. (1976) Coronary arterial smooth muscle contraction by a substance released from platelets: Evidence that it is thromboxane A2. Science 193:1135-1137.
Fiddler G.I., Lumley P. (1990) Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review. Circulation 81:169-178.
Fitzgerald D., Roy L., Catella F., FitzGerald G. (1986) Platelet activation in unstable coronary disease. N Engl J Med 315:983-989.
Granström E., Diczfalusy U., Hamberg M., Hansson G., Malmsten C., Samuelsson B. (1982) Thromboxane A2: Biosynthesis and effects on platelets. Adv Prostaglandin Thromhoxane Leukot Res 10:15-18.
Gresele P., Arnout J., Deckmyn H., Huybrechts E., Pieters G., Vermylen J. (1987) Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J Clin Invest 80:1435-1445.
Gresele P., Deckmyn H., Arnout J., Lemmens J., Janssens W., Vermylen J. (1984) BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man. Lancet 1:991-994.
Hamberg M., Svensson J., Samuelsson B. (1975) Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72:2994-2998.
Hamberg M., Svensson J., Wakabayashi T., Samuelsson B. (1974) Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc Natl Acad Sci USA 71:345-349.
Harris D.N., Hedberg A., Phillips M.B., Michel I.M., Goldenberg H.J., Liu E.C. (1987) 7-Oxabicycloheptane analogs: Modulators of the arachidonate cascade. Adv Prostaglandin Thromboxane Leukot Res 17 A:482-486.
Hechtman D.H., Kroll M.H., Gimbrone M.A. Jr., Schafer A.I. (1991) Platelet interaction with vascular smooth muscle in synthesis of prostacyclin. Am J Physiol 260.
Heylen L., De Clerck F., Somers Y., Leysen J.E. (1991) Thromboxane A2/prostaglandin endoperoxide (TXA2/PG-END) receptor binding properties in human platelets of ridogrel, a combined TXA2 synthase inhibitor-TXA2/PG-END receptor antagonist. Blood Coagul Fibrinolysis 2:617-621.
Kundu S., Heilmann E., Sio R., Garcia C., Davidson R., Ostgaard R. (1995) Description of an in vitro platelet function analyzer-PFA-100. Semin Thromb Hemost 21:106-112.
Masereel B., Damas J., Fontaine J. (1999) Thromboxane A2 receptor antagonism in man and rat by a sulphonylcyanoguanidine (BM-144) and a sulphonylurea (BM-500). J Pharm Pharmacol 51:695-701.
Monshizadegan H., Hedberg A., Webb M.L. (1992) Characterization of binding of a specific antagonist, [3H]-SQ 29,548, to soluble thromboxane A2/prostaglandin H2 (TP) receptors in human platelet membranes. Life Sci 51:431-437.
Needleman P., Wyche A., Raz A. (1979) Platelet and blood vessel arachidonate metabolism and interactions. J Clin Invest 63:345-349.
Needleman P., Moncada S., Bunting S., Vane J., Hamberg M., Samuelsson B. (1976) Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature 261:558-560.
Nijkamp F.P., Moncada S., White H.L., Vane J.R. (1977) Diversion of prostaglandin endoperoxide metabolism by selective inhibition of thromboxane A2 biosynthesis in lung, spleen or platelets. Eur J Pharmacol 44:179-186.
Ogletree M.L., Harris D.N., Greenberg R., Haslanger M.F., Nakane M. (1985) Pharmacological actions of SQ-29,548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther 234:435-441.
Patscheke H., Stegmeier K. (1984) Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets. Thromb Res 33:277-288.
Pawlowski N., Kaplan G., Hamill A., Cohn Z., Scott W. (1983) Arachidonic acid metabolism by human monocytes. Studies with platelet-depleted cultures. J Exp Med 158:393-412.
Riess H., Hiller E., Reinhardt B., Bräuning C. (1984) Effects of BM 13.177, a new antiplatelet drug in patients with atherosclerotic disease. Thromb Res 35:371-378.
Saldeen P., Nilsson I., Saldeen T. (1983) Increased synthesis of thromboxane B2 and 6-keto-PGF1alpha in hand veins from patients with deep venous thrombosis. Thromb Res 32:461-467.
Saldeen T., Saldeen P., Nichols W., Lawson D., Nicolini F., Mehta J. (1993) Increased production of thromboxane A2 by coronary arteries after thrombolysis. Am Heart J 125:277-284.
Stegmeier K., Pill J., Müller-Beckmann B. (1984) The pharmacological profile of the thromboxane A2 antagonist BM 13.177. A new anti-platelet and anti-thrombotic drug. Thromb Res 35:379-395.
(1994) Randomized trial of ridogrel a combined thromboxane A2 synthase inhibitor thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. Circulation 89:588-595.
Uchida T., Kido H., Yamanaga K., Okita M., Watanabe M. (1992) A novel loop diuretic, torasemide, inhibits thromboxane A2-induced contraction in the isolated canine coronary artery. Prostaglandins Leukot Essent Fatty Acids 45:121-124.
Verstraete M. (1993) Thromboxane synthase inhibition, thromboxane/endoperoxide receptor blockage and molecules with the dual property. Drugs Today 29:221-232.
Watts I.S., Wharton K.A., White B.P., Lumley P. (1991) Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: Comparison of anti-aggregatory efficacy in human platelets. Br J Pharmacol 102:497-505.
Joseph J.E., Machin S.J. (1997) New antiplatelet drugs. Blood Rev 11:178-190.